ARTICLE | Finance
Trendy Agios
Cancer metabolism company Agios boosts cash pile, expands into Orphan diseases
November 21, 2011 8:00 AM UTC
Cancer metabolism play Agios Pharmaceuticals Inc. will use last week's $78 million series C round to expand its research into the metabolic pathways involved in genetic disorders that are caused by mutations or defects of single metabolic genes.
That puts Agios at the nexus of two trendy fields: cancer metabolism and Orphan diseases...